Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Medpace Holdings Inc Market Cap
The Medpace Holdings Inc (MEDP) share price is expected to increase by 15.71% over the next year. This is based on calculating the average 12-month share price estimate provided by 7 stock analysts who have covered MEDP. Price targets range from $336 at the low end to $435 at the high end. The current analyst consensus for MEDP is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
MEDP is a stock in Health Care which has been forecasted to be worth $406.91 as an average. On the higher end, the forecast price is $435 USD by Ann Hynes from Mizuho and on the lower end MEDP is forecasted to be $336 by Justin Bowers from Deutsche Bank.
These are the latest 20 analyst ratings of MEDP.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jailendra Singh Truist Securities | Hold | $415 | Initiates | Aug 1, 2024 |
| Eric Coldwell Baird | Outperform | $430 | Maintains | Jul 24, 2024 |
| Sandy Draper Guggenheim | Buy | $432 | Maintains | Jul 24, 2024 |
| Justin Bowers Deutsche Bank | Hold | $336 | Maintains | Jul 24, 2024 |
| Charles Rhyee TD Cowen | Buy | $434 | Maintains | Jul 24, 2024 |
| Max Smock William Blair | Outperform | Reiterates | Jul 23, 2024 | |
| Eric Coldwell Baird | Outperform | $469 | Maintains | Jul 8, 2024 |
| Charles Rhyee TD Cowen | Buy | $452 | Initiates | May 29, 2024 |
| Ann Hynes Mizuho | Buy | $435 | Initiates | May 28, 2024 |
| Sandy Draper Guggenheim | Buy | $464 | Maintains | Apr 24, 2024 |
| Eric Coldwell Baird | Outperform | $454 | Maintains | Apr 24, 2024 |
| David Windley Jefferies | Buy | $450 | Upgrade | Apr 23, 2024 |
| Justin Bowers Deutsche Bank | Hold | $395 | Initiates | Mar 18, 2024 |
| John Sourbeer UBS | Buy | $480 | Maintains | Mar 8, 2024 |
| John Sourbeer UBS | Buy | $452 | Upgrade | Feb 15, 2024 |
| Eric Coldwell Baird | Outperform | $408 | Maintains | Feb 14, 2024 |
| Eric Coldwell Baird | Outperform | $312 | Maintains | Jan 17, 2024 |
| Eric Coldwell Baird | Outperform | $289 | Upgrade | Oct 24, 2023 |
| Sandy Draper Guggenheim | Buy | $273 | Maintains | Jul 25, 2023 |
| Sandy Draper Guggenheim | Buy | $252 | Upgrade | May 8, 2023 |
When did it IPO
2016
Staff Count
5,800
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Dr. August James Troendle M.D.
Market Cap
$11.88B
In 2023, MEDP generated $1.89B in revenue, which was a increase of 29.17% from the previous year. This can be seen as a signal that MEDP's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Medpace Holdings, Inc. for potential securities law violations, including possible misleading statements affecting investors.
Why It Matters - Medpace Holdings faces potential legal issues due to alleged securities law violations, which could impact its stock price and investor confidence.
Wed, 11 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Medpace Holdings, Inc. for potential securities law violations, including false or misleading statements affecting investors.
Why It Matters - The investigation into Medpace for potential securities law violations may lead to legal liabilities, impacting its stock value and investor confidence.
Wed, 11 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Analyst recommendations significantly impact stock prices, influencing investor decisions to buy, sell, or hold, according to media reports on rating changes.
Why It Matters - Analyst recommendations can significantly sway stock prices, impacting investment decisions and market sentiment, making them crucial for timing buy, sell, or hold strategies.
Tue, 10 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - HealthEquity (HQY) and Medpace (MEDP) are notable stocks in the Medical Services sector, attracting investor interest for potential undervaluation.
Why It Matters - Investors can identify potential undervalued stocks in the Medical Services sector by comparing HealthEquity and Medpace, which may lead to better investment decisions and returns.
Sat, 07 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Medpace Holdings, Inc. for potential securities law violations, including possible false statements and undisclosed information relevant to investors.
Why It Matters - The investigation into Medpace for potential securities law violations could signal legal risks, impact stock valuation, and affect investor confidence, influencing trading decisions.
Mon, 09 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Schall Law Firm is investigating Medpace Holdings, Inc. for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters - Investigations into Medpace for potential securities law violations could impact stock value, investor confidence, and lead to legal repercussions, affecting investment decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
